The US Food and Drug Administration (FDA) has approved remestemcel-L (Ryoncil, Mesoblast Ltd), an allogeneic bone marrow‒derived mesenchymal stromal cell (MSC) therapy for steroid-refractory acute ...

Bone marrow plays a crucial role in maintaining hematopoietic stem cells and bone homeostasis. However, research has been hindered by a lack of effective markers and monoclonal antibodies to ...

New research by an interdisciplinary team in Lithuania has revealed a promising and unconventional approach to cartilage regeneration. Using extracellular vesicles derived from menstrual blood stromal ...

Stem cells form the backbone of many cell-based therapies due to their unique properties, including the ability to self-renew and differentiate to many cell types. Multiple cell therapies deliver ...

RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication. RYONCIL is the first FDA-approved therapy for children aged 2 months and older, including adolescents and teenagers ...

The ORR was 70% in patients treated with remestemcel-L, with 30% having a complete response and 41% having a partial response. The Food and Drug Administration (FDA) has approved Ryoncil ® ...

Please provide your email address to receive an email when new articles are posted on . Taking beta blockers may raise mortality risk for HSCT recipients due to suppression of signals from nerves that ...

New research by an interdisciplinary team in Lithuania has revealed a promising and unconventional approach to cartilage ...